On a per-share basis, the
The results beat
The drug developer posted revenue of
Bellus shares have decreased 16% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from
Copyright by Automated Insights, Inc. All rights reserved., source